Posted by Michael Wonder on 18 Oct 2016
The biggest pharma election risk is in California
16 October 2016 - Political risks surrounding high drug prices aren’t limited to the presidential campaign.
The possibility of Democrats capturing the presidency and Congress is worrying enough for pharmaceutical and other health-care investors. But that isn’t the full extent of risk that shareholders face this election season.
True, presidential front-runner Hillary Clinton has proposed numerous ideas to curb the pricing power of drug manufacturers such as allowing Medicare to negotiate prices with manufacturers. Most of her proposals would require an act of Congress to enact, which becomes more likely the better Democrats do at the voting booths.
